Carbiotix launches simplified & lower price gut health test
Carbiotix (publ) ("Carbiotix") announces today that the company has launched a new competitive gut health test within its OneGut second generation diagnostic platform. The new “Basic” test, which will be sold at a lower price, follows the launch of the company’s “Standard” test in February of 2020 and now provides an even more cost effective option for the long-term monitoring of gut health. The launch of the Basic test reinforces Carbiotix market position as a leading provider of white label consumer gut health tests for food & beverage, supplement and pharmaceutical companies, as well as providers of health and wellness services.
While Carbiotix Standard gut health test is based on a Next Generation Sequencing (NGS) analysis, the Basic test is based on a Polyermase Chain Reaction (PCR) analysis. This allows the price of the test to be be cut by 50% (49 Euros instead of 99 Euros), while still offering the test in triplicate (three samples) and thus providing a much more reliable test than other tests on the market today. The PCR test also provides more useful data, allowing users to monitor over time the actual presence of key Short Chain Fatty Acids (SCFAs), a key gut health metric to assess the real impact of an intervention such as a probiotic or prebiotic.
Kristofer Cook, CEO for Carbiotix, comments
“The launch of our Basic gut health test marks the beginning of long-term gut health monitoring becoming affordable and providing useful feedback as to whether a gut health intervention is having a positive effect on overall gut health. Inspired by our first generation Fiber Loving Bacteria (FLB) index, the Basic service allows us to provide a more cost effective and useful gut health test and is in line with our long term ambition to further reduce the cost and thus increase the accessibility of long term gut health monitoring.”
Kristofer Cook continues,
“We are also happy to announce that the Basic test will be a standard feature of our LinkGut white label gut health testing service, thus providing more testing alternatives for food & beverage, supplement and pharmaceutical companies, as well as providers of health and wellness services. This is extremely important as we transition to LinkGut becoming our primary channel to market for testing services, allowing us to leverage the market reach of our partners, reduce customer acquisition costs, and focus our efforts on the 100 million Euro global market for consumer gut health testing growing at 12% per year (1)(2). This strategy will also allow us to create long term relationships with potential customers of our AXOS ingredient, by being able to both supply an ingredient and validate its efficacy using our diagnostic platform.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 6 August 2020.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.